Filial Sons of Hegel: Death, Freedom, and Forever Hegelian Events

BackgroundLegal and ethical questions arise regarding disseminating genetic research results to family members in the event of a research participant's death; failure to return or return to legal next of kin or estate executor may not reflect participant desires. We sought to determine participant preferences for whether and to whom they would like their data released in the case of their death prior to receiving genomic results, focusing on whether the person selected was also their estate executor.MethodsThe University of Washington NEXT Medicine Study of the Clinical Sequencing Exploratory Research program previously reported participant preferences regarding designating an individual to receive genomic results in the event of death, including whether they want results shared, and if so, with what person. Participants were also asked whether this designee is executor of their will or estate.ResultsTo date, 61 individuals were asked about the concordance of their study designee and legal representative: 42 (69%) reported having a will or estate plan and of these, 14 (33%) chose someone other than their executor to receive their results. For the 14 who chose someone other than their estate executor to receive genetic results, 12 (86%) chose a family member, typically a biological relative, as their designee. Those with a different genomic designee than their executor were less likely to be partnered (P = 0.0024). For those partnered participants without an estate plan, spouses were not always chosen for return of genomic results.ConclusionFor one‐third of our participants, the individual deemed most appropriate by the participant to receive their genomic results was not the executor. In the absence of an explicit designation, HIPAA may prohibit access to genomic results to persons other than the executor; hence asking for designation at the time of study enrollment (or initiation of clinical testing) is important.

Objective: To evaluate the feasibility and safety of the LAmbre occluder for large-diameter left atrial appendage occlusion. Methods: This study was a retrospective cohort study. Patients with large orifice of the left atrial appendage (≥31 mm) and occlusion with the LAmbre device in the Arrhythmia Center of Ningbo First Hospital were included from June 2018 to March 2020. Baseline data were collected and major perioperative complications of left atrial appendage occlusion (including death, stroke, instrumental embolism, cardiac tamponade, and major bleeding events) were recorded. Patients were followed up 45 days, 6 months and 12 months after surgery. The shunt and device-related thrombosis were recorded by esophageal cardiac ultrasound or pulmonary vein CT, and the occurrence of postoperative thromboembolism, bleeding events, death and other serious adverse events were recorded. Results: The average age and left atrial appendage ostial dimension of 32 patients (37.5% women) included in this research were (70.4±8.4) years old and (34.4±2.9) mm. The LAmbre device was successfully implanted in 31(96.9%) patients. No major complications occurred during the perioperative period. During the 12-month follow-up, pericardial tamponade occurred in 1(3.2%) patient and was recovered after treatment. There was no occluder edge shunt>5 mm in patients followed up by esophageal echocardiography. No significant peri-device leak, device-related thrombus, thromboembolism or death event has occurred. Conclusion: The LAmbre occluder may be feasible and safe for large-diameter left atrial appendage occlusion.

Recent decades data relates between admission hyperglycemia and mortality that increase among acute coronary syndrome(ACS) patients. Aim of study is to assess relationship between hyperglycemia and Cardiac Event, i.e. death, reinfarction among ACS patients. This is a prospective cohort study, which was held on March to April 2014 among 83 ACS patients in CVCU Wahodin Sudorohusodo Hospital. Patients was grouped into two groups, hyperglycemic ACS group and normoglycemic one. Reinfarction and death events at each group was observed within first 30 days after infarction. In this study, it found death and reinfarction events were higher in hyperglycemic group than in normoglycemic group (22 vs 4, RR = 3.7, p=0.026 for death event, and 14 vs 1, RR =8.7, p=0.03 for reinfarction). Conclusion of this study was hyperglycemia is related to reinfartion and death events among ACS patients.

Mantle Cell International Prognostic Index (MIPI) Is a Strong Predictor of the Outcome of Mantle Cell Lymphoma (MCL) in the Rituximab (R) Era.

Retrospective Analysis of 206 Mantle Cell Lymphoma Patients at Diagnosis: Mantle Cell International Prognostic Index (MIPI) Is a Good Predictor of Death Event In Patients Treated Either with Rituximab-Chemotherapy or Rituximab-High-Dose-Chemotherapy

The employer may act in the legal capacity of a natural person or a legal entity. In the former case, the subject of an employment relationship is a natural person per se or a natural person in the capacity of a sole trader or a freelancer. In the latter case, given that a natural person is identified with his/her own enterprise (as they constitute one body), the question arises what happens in the event of a change in the legal status of a natural person as the employer (a holder of a sole proprietorship), which will primarily take place in the event of death or loss of legal capacity. Considering that the labour legislation of the Republic of Serbia does not provide an answer to this question, the author will address this question by seeking answers within the framework of general rules of labour, inheritance, family and company legislation. In that sense, the paper analyzes the effects of death and loss of legal capacity of an employer (a natural person) on the existing employment relations. The author aims to respond to the question whether the employer's death necessarily causes the termination of employment, or whether such employment may be continued by the employer's successors (in which case, it may be considered as the change of employer). In particular, the author focuses on the provisions of the Business Companies Act, which regulate the possibilities to continue conducting the business in the event of the sole trader's death while implicating their shortcomings, unclarities and issues they cause in the interpretation and practical application thereof. In that context, the author examines the legal grounds enabling the successor to take over the sole trader business, the subject matter of such succession, the labour law status of employees, and the possibility for the co-successors' community (a number of natural persons) to act in the capacity of the employer.

An estimated 3,500 people die every day in the UK. If someone at work or their partner or close family member dies, managers and colleagues need to respond appropriately. This book breaks new ground in placing bereavement on the management agenda. It addresses some challenging questions such as: What to say and what not to say? How to balance the needs of the person and the job? How do you get it right in a diverse, multi-cultural workforce? How do you decide what time off is reasonable? How can other people at work help, as well as avoiding making the situation worse? This book is an essential guide for anyone in an organisation who has to take responsibility in the event of death. It covers issues such as what do in the event of a sudden death at work, managing staff who are terminally ill, and practical help after death including funerals. It is a unique and constant point of reference for anyone concerned with one of the most challenging issues to be faced in the workplace.

Drug-induced death of the asexual blood stages of Plasmodium falciparum occurs without typical signs of apoptosis

Irradiation as a possible quarantine treatment for green scale Coccus viridis (Green) (Homoptera: Coccidae)

ABSTRACTAffect fades faster for unpleasant events than for pleasant events (e.g., Walker, Vogl, & Thompson, 1997), which is referred to as the fading affect bias (FAB; Walker, Skowronski, Gibbons, Vogl, & Thompson, 2003). Although research has generally shown that the FAB is a healthy coping mechanism, this same finding has not been demonstrated at a specific level of analysis accounting for particular event types and related individual differences (e.g., Gibbons et al., 2013). Given the strong unpleasant emotions associated with death (Rask, Kaunonen, & Paunonen-Ilmonen, 2002), the current study examined FAB in the context of death events and participant attitudes toward death. General healthy coping was shown by robust FAB across death and control (i.e., everyday) events and by a negative correlation between negative religious coping and FAB. Although healthy coping at a specific level of analysis was supported by increased FAB for participants who held accepting attitudes toward death when they recalled everyday events, it was not supported by decreased FAB for the same participants when they recalled death events. This effect was mediated by rehearsal ratings, not depression. Implications are discussed.

Limited data are available for the comparison between different non-vitamin K antagonist oral anticoagulants (NOACs) on clinical outcomes. We aimed to provide evidence of different NOACs for patients with non-valvular atrial fibrillation (NVAF). Electronic databases were searched from inception through 22 March 2020 to identify eligible studies in which clinical outcomes (stroke, systemic embolism [SE], bleeding or death events) were directly compared between different NOACs. 29 real-world studies enrolled more than 700,000 patients were included. Compared with dabigatran, apixaban had higher risk of death (OR 1.07), major bleeding (1.43), GI bleeding (1.64), ischaemic stroke and stroke/SE events (1.10); rivaroxaban had higher risk of death (1.28), major bleeding (1.24), GI bleeding (1.14) and ischaemic stroke (1.08). Compared with rivaroxaban, apixaban had lower risk of death (0.8), major bleeding (0.56) and ischaemic stroke events (0.71). Compared with edoxaban, rivaroxaban had higher risk of major bleeding (2.83), GI bleeding (5.18) and ischaemic stroke (2.28). In view of the global burden of disease and the routine use of NOACs worldwide, the findings have immediate and important implications. Our data suggested that apixaban might be the priority choice in prevention of bleeding and stroke and dabigatran could be the priority choice in prevention of death events. This systematic review and meta-analysis were conducted and reported according to the Preferred Reporting Items for Systematic Reviews (PRISMA), Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines and was registered with PROSPERO (CRD42019140553).

There are no shared decision-making frameworks for selecting blood pressure (BP) targets for individuals with hypertension. This study addressed whether results from the SPRINT (Systolic Blood Pressure Intervention Trial) could be tailored to individuals using predicted risks and simulated preferences. Among 8202 SPRINT participants, Cox models were developed and internally validated to predict each individual's absolute difference in risk from intensive versus standard BP lowering for cardiovascular events, cognitive impairment, death, and serious adverse events (AEs). Individual treatment effects were combined using simulated preference weights into a net benefit, which represents a weighted sum of risk differences across outcomes. Net benefits were compared among those above versus below the median AE risk. In simulations for which cardiovascular, cognitive, and death events had much greater weight than the AEs of BP lowering, the median net benefit was 3.3 percentage points (interquartile range [IQR], 2.0-5.7), and 100% of participants had a net benefit favoring intensive BP lowering. When simulating benefits and harms to have similar weights, the median net benefit was 0.8 percentage points (IQR, 0.2-2.2), and 87% had a positive net benefit. Compared with participants at lower risk of AEs from BP lowering, those at higher risk had a greater net benefit from intensive BP lowering despite experiencing more AEs (P<0.001 in both simulations). Most SPRINT participants had a predicted net benefit that favored intensive BP lowering, but the degree of net benefit varied considerably. Tailoring BP targets using each patient's risks and preferences may provide more refined BP target recommendations.

Ascertaining Death Events in a Pragmatic Clinical Trial: Insights From the TRANSFORM-HF Trial

The results of theoretical and experimental studying of birth and death events and evolution process of degenerated combined mode singularities in low-mode optical fiber are presented in this paper. It is shown, that a topological birefringence phenomenon in a fiber is manifested as the birth, death and metamorphosis events of field singularities and it could be divided into two stages: (1) the wavefield rotation around the optical axis (circular birefringence); (2) the cyclic deformation of the field structure (linear birefringence). To describe the field state at the intermediate fiber cross-section, one was introduced the characteristic surface given by the transversal components of vector Poynting. The wave process flow in this field is characterized by topological reactions of the singular points on the characteristic surface.

The current spatial pattern of a population is the result of previous individual birth, death, and dispersal events. We present a simple model followed by a comparative analysis for a species-rich plant community to show how the current spatial aggregation of a population may hold information about recent population dynamics. Previous research has shown how locally restricted seed dispersal often leads to stronger aggregation in less abundant populations than it does in more abundant populations. In contrast, little is known about how changes in the local abundance of a species may affect the spatial distribution of individuals. If the level of aggregation within a species depends to some extent on the abundance of the species, then changes in abundance should lead to subsequent changes in aggregation. However, an overall change of spatial pattern relies on many individual birth and death events, and a surplus of deaths or births may have short-term effects on aggregation that are opposite to the long-term change predicted by the change in abundance. The change in aggregation may therefore lag behind the change in abundance, and consequently, the current aggregation may hold information about recent population dynamics. Using an individual-based simulation model with local dispersal and density-dependent competition, we show that, on average, recently growing populations should be more aggregated than shrinking populations of the same current local abundance. We tested this hypothesis using spatial data on individuals from a long-term tropical rain forest plot, and find support for this relationship in canopy trees, but not in understory and shrub species. On this basis we argue that current spatial aggregation is an important characteristic that contains information on recent changes in local abundance, and may be applied to taxonomic groups where dispersal is limited and within-species aggregation is observed.